Misplaced Pages

Hetrombopag

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Hengqu) Chemical compound

Pharmaceutical compound
Hetrombopag
INN: Hetrombopag
Clinical data
Trade namesHengqu
Other namesRafutrombopag olamine; rafutrombopag ethanolamine; hetrombopag; SHR-8735; SHR8735
Routes of
administration		Oral
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • 5-diazenyl]phenyl]furan-2-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC25H22N4O5
Molar mass458.474 g·mol
3D model (JSmol)
SMILES
  • CC1=C(C(=O)N(N1)C2=CC3=C(CCCC3)C=C2)N=NC4=CC=CC(=C4O)C5=CC=C(O5)C(=O)O
InChI
  • InChI=InChI=1S/C25H22N4O5/c1-14-22(24(31)29(28-14)17-10-9-15-5-2-3-6-16(15)13-17)27-26-19-8-4-7-18(23(19)30)20-11-12-21(34-20)25(32)33/h4,7-13,28,30H,2-3,5-6H2,1H3,(H,32,33)
  • Key:YATJUTCKRWETAB-UHFFFAOYSA-N

Hetrombopag (also known as rafutrombopag; trade name Hengqu) is a pharmaceutical drug for the treatment of thrombocytopenia and anemia.

It is a non-peptide small‐molecule thrombopoietin receptor agonist.

In China, it is approved for second-line treatment for primary immune thrombocytopenic purpura (ITP) and severe aplastic anemia (SAA) in adults.

References

  1. Mei H, Chen X, Zhou J, Luo J, Shi Q, Liu J, et al. (January 2022). "Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study". Annals of Translational Medicine. 10 (2): 30. doi:10.21037/atm-21-4361. PMC 8848441. PMID 35282136.
  2. Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, et al. (February 2021). "A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia". Journal of Hematology & Oncology. 14 (1): 37. doi:10.1186/s13045-021-01047-9. PMC 7905908. PMID 33632264.
  3. Chang H, Pan L, Jia Y, Xiang B, Huang X, Guo Y, et al. (2023). "Effectiveness and Safety of Hetrombopag-Containing Therapy in Patients with Severe Aplastic Anemia: A Multicenter Real-World Study". Blood. 142: 5631. doi:10.1182/blood-2023-185469.
  4. ^ Syed YY (September 2021). "Hetrombopag: First Approval". Drugs. 81 (13): 1581–1585. doi:10.1007/s40265-021-01575-1. PMID 34357499.
Antihemorrhagics (B02)
Antihemorrhagics
(coagulation)
Systemic
Vitamin K
Coagulation
factors
Other
systemic
Local
Antifibrinolytics
Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.

Categories:
Hetrombopag Add topic